Triple-Drug attack shows promise against tough skin cancer

NCT ID NCT04091750

Ongoing Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Mar 09, 2026 · Last updated May 16, 2026 · Updated 9 times

Summary

This study tests a combination of three drugs (nivolumab, ipilimumab, and cabozantinib) in people with advanced melanoma that cannot be removed by surgery. The goal is to see if this triple therapy can keep the cancer from growing for at least one year. Participants receive the drugs for up to two years, and the study tracks tumor shrinkage, side effects, and survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Lombardi Comprehensive Cancer Center

Washington D.C., District of Columbia, 20007, United States
Medstar Franklin Square Medical Center, Harry and Jeanette Weinberg Cancer Institute

Baltimore, Maryland, 21237, United States

Conditions

Explore the condition pages connected to this study.

MELANOMA